Utilization of Hemodiafiltration as Treatment Modality in Renal Replacement Therapy for End-Stage Renal Disease Patients – A Global Perspective

2011 ◽  
pp. 163-169 ◽  
Author(s):  
Jan-Michael Sichart ◽  
Stefan Moeller
Keyword(s):  
Renal Replacement Therapy ◽  
Renal Disease ◽  
Replacement Therapy ◽  
End Stage Renal Disease ◽  
Treatment Modality ◽  
Global Perspective ◽  
Stage Renal Disease ◽  
End Stage

Survival During Renal Replacement Therapy for Diabetic End-Stage Renal Disease in Pima Indians

Diabetes Care ◽  
1996 ◽  
Vol 19 (12) ◽  
pp. 1333-1337 ◽  
Author(s):  
R. G. Nelson ◽  
R. L. Hanson ◽  
D. J. Pettitt ◽  
W. C. Knowler ◽  
P. H. Bennett
Keyword(s):  
Renal Replacement Therapy ◽  
Renal Disease ◽  
Replacement Therapy ◽  
End Stage Renal Disease ◽  
Pima Indians ◽  
Stage Renal Disease ◽  
End Stage

Patient-nephrologist prognostic awareness and discordance in end stage renal disease on renal replacement therapy

2020 ◽  
Vol 52 (4) ◽  
pp. 765-773
Author(s):  
Sassine Ghanem ◽  
Sami Hossri ◽  
Nicholas Fuca ◽  
Evgenia Granina ◽  
Samer Saouma ◽  
...  
Keyword(s):  
Renal Replacement Therapy ◽  
Renal Disease ◽  
Replacement Therapy ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

Access to and characteristics of palliative care-related hospitalization in the management of end-stage renal disease patients on renal replacement therapy in France

Nephrology ◽  
2017 ◽  
Vol 22 (8) ◽  
pp. 598-608 ◽  
Author(s):  
Cécile Couchoud ◽  
Del Bello Arnaud ◽  
Thierry Lobbedez ◽  
Sylvie Blanchard ◽  
François Chantrel ◽  
...  
Keyword(s):  
Palliative Care ◽  
Renal Replacement Therapy ◽  
Renal Disease ◽  
Replacement Therapy ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

Neurological Manifestations of Renal Disease

2017 ◽  
Author(s):  
Joshua S. Hundert ◽  
Rashmi Verma ◽  
Ritika Suri ◽  
Anika T. Singh ◽  
Ajay Singh
Keyword(s):  
Chronic Kidney Disease ◽  
Central Nervous System ◽  
Renal Replacement Therapy ◽  
Renal Disease ◽  
Replacement Therapy ◽  
End Stage Renal Disease ◽  
Clinical Syndrome ◽  
Neurological Manifestations ◽  
Stage Renal Disease ◽  
End Stage

In the United Syates, chronic kidney disease (CKD) affects approximately 5% to 10% of the general population. It is estimated that about 20 million Americans have some degree of CKD. Central nervous system (CNS) abnormalities are common in patients with CKD, especially in those individuals with end stage renal disease (ESRD) who require renal replacement therapy, such as dialysis or transplant. Neurological symptoms in patients with CKD may range from mild altered sensorium and cognitive dysfunction to tremors and coma. By the time patients require renal replacement therapy, some patients may have uremia, a clinical syndrome with protean manifestations.

P0273THE EFFECT OF END STAGE RENAL DISEASE AND RENAL REPLACEMENT THERAPY ON B LYMPHOCYTE SUBPOPULATIONS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Dimitra Vasileia Daikidou ◽  
MARIA STANGOU ◽  
Erasmia Sampani ◽  
Vasiliki Nikolaidou ◽  
Despoina Asouchidou ◽  
...  
Keyword(s):  
B Cells ◽  
Renal Replacement Therapy ◽  
Renal Disease ◽  
B Cell ◽  
Replacement Therapy ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
The Impact ◽  
Esrd Patients

Abstract Background and Aims End-stage renal disease (ESRD) is linked to immunodeficiency, which makes a significant contribution to morbidity and mortality. Disturbances in innate and adaptive immunity have been described in patients on dialysis, although their association with the therapy itself is yet to be defined. The present study aimed to assess the impact of dialysis on B cell subpopulations Method B cells (CD19+) and their subsets B1a (CD19+CD5+), naive (CD19+CD27−), memory (CD19+CD27+), (CD19+BAFFR+) and (CD19+IgM+), were quantified using flow-cytometry of in the peripheral blood of ESRD patients, the first day on dialysis (T0), and repeated 6 months later (T6). The results were compared to age-matched healthy control group. Exclusion criteria were age <18 or>75 years, active autoimmune or chronic inflammatory disease, medical history of malignancy, corticosteroids or immunosuppresive treatment for the last 12 months Results Pre dialysis ESRD patients had reduced lymphocyte count (1527±646μ/L vs. 2459±520μ/L, p<0.001) and B cell (CD19+) count (82.7±59.5μ/L vs. 177.6±73.8μ/L, p<0.001) compared to controls, whereas the percentages of B cell subsets were not particularly affected, except for B1a subset which presented a significant increase (4.1±3.6% vs. 0.7±0.7% p<0.001). In 17 patients who had a follow-up sample 6 months later, the percentage of most subsets was reduced (CD19+CD5+: 1.02±0.8% from 3.6±4.6%, p=0.015, Naive: 40±22.3% from 61±17.4%, p=0.001, CD19+BAFF+:75.8±12.6% from 82.1±9.1%, p=0.04,), apart from memory B cells percentage, which was increased (49.4±52.1% from 32,9±35,5%, p=0.01) and CD19+ IgM+ percentage, which was unaffected . Conclusion A significant reduction of almost all subsets of B cells was noticed in patients with ESRD on pre-dialysis stage. Furthermore, the initiation of renal replacement therapy may be linked to further alterations in B cells subpopulations, especially at their early stages.

Sign in / Sign up

Export Citation Format

Share Document